AstraZeneca announced that osimertinib (Tagrisso) improved overall survival (OS) in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations. According to the press release, data from the phase 3 FLAURA trial showed that osimertinib demonstrated a statistically significant and clinically meaningful improvement in OS compared with erlotinib or gefitinib. The FLAURA trial met its primary endpoint in 2017, showing a statistically significant and clinically meaningful improvement in progression-free survival. 
 
A recent study found that pregnant women may be less likely to develop gestational diabetes when switching to a Mediterranean diet from their usual eating habits, Reuters reported. According to the article, the researchers studied 1252 women who were at high risk of developing gestational diabetes during pregnancy and assigned approximately half of the women to a Mediterranean diet. Compared with women who did not change their eating habits, females who switched to the Mediterranean diet were 35% less likely to develop gestational diabetes, the article reported.
 
A new study suggests that second primary cancers (SPCs) may appear more frequently in patients with malignant melanoma if there is a prior family history of cancer, The American Journal of Managed Care reported. According to the article, the study evaluated the relative risks and causes of deaths from SPCs in patients with a malignant melanoma diagnosis between 1958 and 2015. Overall, the study showed that a family history of lung, ovary, kidney, bladder, and skin cancers and leukemia more than doubled the risk of SPC, the article reported